Karim brings to Silver Creek Pharmaceuticals over 2 decades of leadership in drug discovery and development. He most recently served as President, CEO, and Board Member at Second Genome, where he joined in 2014 as Chief Scientific Officer. Prior to Second Genome, Karim was Vice President of R&D at Pfizer where he oversaw external R&D and innovation for Pfizer Research Units in areas spanning immune, vaccines, anti-infective, cardiovascular, metabolic, endocrine,neurological, and rare disease areas. He was also a founder of Modus BioMedicine, a biotechstart-up dedicated to treatments for transplantation and autoimmune diseases and held several senior roles during his nine years at Roche Pharmaceuticals,including Head of Inflammation Discovery Research Pharmacology. He currently serves on the board of directors of MaaT Pharma (Euronext: MaaT) and Genevive Bio, a company he co-founded in2023. Karim earned his doctorate in Biochemistry from University College London and completed postdoctoral fellowships at both the Cardiovascular Research Institute at UCSF and Stanford University He holds a bachelor’s degree in biotechnology from the Imperial College of Science, Technology, and Medicine in London. He is an author on over 50 peer reviewed scientific publications and issued/published patents.